Lennon David James 4

What Happened
Lennon David James, CEO of Whitehawk Therapeutics (WHWK), received an equity award/acquisition of 51,021 shares on May 14, 2026. The award is reported at $3.92 per share for a total reported value of $200,002. This was an award/acquisition (code A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-14; Reported filing date: 2026-05-18 (filed 4 days after the transaction, which exceeds the typical 2-business-day Form 4 deadline).
• Price per share: $3.92; Total value: $200,002.
• Shares acquired: 51,021 (award/grant).
• Shares owned after transaction: not specified in the provided summary — see the full Form 4 for post-transaction holdings.
• No 10b5-1 plan, tax-withholding, or other footnotes were included in the provided transaction details.

Context
Code A indicates an award or other acquisition (commonly part of executive compensation). Such grants often have vesting conditions or restrictions; check the full Form 4 or company proxy for vesting schedules or restrictions. Because this is an awarded grant rather than an open-market buy, it reflects compensation/retention practices more than an immediate market-driven bullish purchase.